Evidence map›Paper›PMID 36477952›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2022

Behavioral effects of a low molecular weight peptide fraction from Phaseolus vulgaris in rats.

D Graziani, J V V Ribeiro, L C Turones, E A Costa, L L Reis-Silva, E G Araújo, L G F de Paula, M D Ferreira-Junior, R M Gomes, H M Campos and 4 more

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

D GrazianiLaboratório de Neurobiologia de Sistemas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0002-4997-2658
J V V RibeiroLaboratório de Neurobiologia de Sistemas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-3937-1071
L C TuronesLaboratório de Farmacologia de Produtos Naturais e Sintéticos, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-4646-5682
E A CostaLaboratório de Farmacologia de Produtos Naturais e Sintéticos, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-1996-0901
L L Reis-SilvaLaboratório de Neurobiologia de Sistemas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-1799-1106
E G AraújoLaboratório Multiusuário de Análise de Moléculas, Células e Tecidos, Escola de Veterinária e Zootecnia, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0002-0242-2827
L G F de PaulaLaboratório Multiusuário de Análise de Moléculas, Células e Tecidos, Escola de Veterinária e Zootecnia, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0002-6058-0495
M D Ferreira-JuniorLaboratório de Fisiologia Endócrina e Metabolismo, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-0490-1212
R M GomesLaboratório de Fisiologia Endócrina e Metabolismo, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0002-9012-3287
H M CamposLaboratório de Farmacologia Bioquímica e Molecular, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0001-8032-3771
P C GhediniInstituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Goiânia Oeste, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-2104-4064
K A BatistaInstituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Goiânia Oeste, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-4396-032X
K F FernandesLaboratório de Química de Polímeros, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0002-6558-5447
C H XavierLaboratório de Neurobiologia de Sistemas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-4006-8213
Universidade Federal de Goiás · BRFundação de Apoio a Pesquisa do Estado de Goiás · BRInstituto Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seminal studies stated that bean proteins are efficient neuronal tracers with affinity for brain tissue. A low molecular weight peptide fraction (<3kDa) from Phaseolus vulgaris (PV3) was previously reported to be antioxidant, non-cytotoxic, and capable of reducing reactive oxygen species and increasing nitric oxide in cells. We evaluated the effects of PV3 (5, 50, 100, 500, and 5000 µg/kg) on behavior and the molecular routes potentially involved. Acute and chronic PV3 treatments were performed before testing Wistar rats: i) in the elevated plus-maze (EPM) to assess the anxiolytic-like effect; ii) in the open field (OF) to evaluate locomotion and exploration; and iii) for depression-like behavior in forced swimming (FS). Catecholaminergic involvement was tested using the tyrosine hydroxylases (TH) enzyme inhibitor, α-methyl-DL-tyrosine (AMPT). Brain areas of chronically treated groups were dissected to assess: i) lipid peroxidation (LPO); ii) carbonylated proteins (CP); iii) superoxide dismutase (SOD) and catalase (CAT) enzymatic activities. Neuronal nitric oxide synthases (nNOS) and argininosuccinate synthase (ASS) protein expression was evaluated by western blotting. Acute treatment with PV3 increased the frequency and time spent in the EPM open arms, suggesting anxiolysis. PV3 increased crossing episodes in the OF. These PV3 effects on anxiety and locomotion were absent in the chronically treated group. Acute and chronic PV3 treatments reduced the immobility time in the FS test, suggesting an antidepressant effect. TH inhibition by AMPT reverted acute PV3 effects. PV3 decreased LPO and CP levels and SOD and CAT activities, whereas nNOS and ASS were reduced in few brain areas. In conclusion, PV3 displayed central antioxidant actions that are concomitant to catecholaminergic-dependent anxiolytic and antidepressant effects.

Indexed as

PhaseolusAnimalsMolecular WeightNitric OxidePeptidesRatsRats, WistarTyrosineNitric OxidePeptidesTyrosine

Identifiers

PMID36477952
PMCPMC9728632
OpenAlexW4311585892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.